However, the utility of EHR data in clinical effectiveness studies may be limited by missing data, unmeasured confounding, and imperfect outcome surveillance. David Merola, 1, 2 Jessica Young, 2, 3 Deborah Schrag, 4 Kueiyu Joshua Lin, 1, 2, 5 Nicholas Robert, 6 Sebastian Schneeweiss 1, 2ġDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 2Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA 3Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, USA 4Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School New York, New York, NY, USA 5Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 6Ontada, Irving, TX, USAĬorrespondence: David Merola, Email īackground: The use of electronic health records (EHR) data to assess drug effectiveness in clinical oncology practice is of great interest to regulators, clinicians, and payers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |